Resero Analytics Launches TurboLIMS, a Cloud LIMS for GLP and Non-GLP Studies

Resero Analytics launched TurboLIMS on November 12, 2026, a cloud-based laboratory information management system for GLP and non-GLP studies in toxicology, pharmacology, pharmacokinetics and toxicokinetics. The company announced the launch in a Business Wire release. TurboLIMS is commercially available now to pharmaceutical and biotechnology companies and contract research organizations conducting GLP and non-GLP in vivo studies.

How TurboLIMS Fits Into TurboPlatform

TurboLIMS is a core component of Resero Analytics's TurboPlatform, which spans study design, electronic data capture, reporting and SEND readiness. Data collected in TurboLIMS flow directly into TurboToxicology for analysis, interpretation and generation of interim and final reports. The system uses the study protocol to drive scheduling, sample labeling and electronic data collection, which the company said eliminates redundant data entry common to legacy LIMS.

TurboLIMS transfers results from hematology, coagulation, chemistry and urinalysis analyzers into the study record, mapped to the appropriate parameters and species. Laboratory balances transmit body weights into electronic data capture forms, and configurable sample labels draw on study, animal, sample and collection information already recorded in the system. "An instrument result becomes useful study data when it is tied to the correct animal, study activity and timepoint," said Anil Gunturu, Chief Technology Officer at Resero Analytics. "TurboLIMS preserves that context as data move from laboratory instruments into the study record, giving scientists a reliable basis for reviewing results, interpreting findings and preparing reports."

"Choosing a new LIMS is an opportunity to improve how your laboratory works," said Dave Watson, PhD, Founder and Chief Executive Officer of Resero Analytics. "Your investment should deliver greater laboratory efficiency, faster access to study results and a shorter path from data collection to high-quality reports."

Envol Biomedical scientists and technicians helped define TurboLIMS requirements and tested workflows in their laboratory. "Our team helped shape TurboLIMS around the realities of running studies," said Jake McDonald, PhD, Chief Executive Officer of Envol Biomedical. "It helps our scientists execute studies faster and more efficiently while maintaining the quality and traceability our customers expect."

Resero's Audit Trail and Validation Footprint

Resero Analytics was founded in 2018 in Indianapolis, Indiana, according to akta.pro company records, to build a unified nonclinical scientific-operations platform as a challenger to fragmented legacy LIMS. The same records list 100% audit trail coverage through a single audit-trail system across all platform applications, and a single validation framework in place of fragmented legacy systems that require multiple validation cycles. TurboLIMS supports GLP-regulated and non-GLP research with role-based access, electronic signatures and audit trails designed to support 21 CFR Part 11 compliance, and corrections preserve change history and require renewed signatures.

SEND Export Planned for 2027

TurboLIMS captures study data using controlled terminology and a structure that supports SEND package generation with minimal manual effort. SEND dataset export is planned for 2027, including support for core requirements of SENDIG 4.0. Resero Analytics directs customers to schedule a TurboLIMS demonstration on its website.